

We Claim:

1. Use of a bisphosphonate in the preparation of a medicament for the treatment of osteoporosis post hip fracture to prevent or reduce subsequent osteoporotic skeletal fractures in a patient in need of such treatment, said patient having undergone recent repair of the hip fracture.
2. A method for the treatment of osteoporosis post-hip fracture to prevent or reduce subsequent osteoporotic skeletal fractures in a patient in need of such treatment, which method comprises administering an effective amount of a bisphosphonate to said patient, said patient having recently undergone recent repair of the hip fracture.
3. A use according to claim 1 or method according to claim 2, wherein administration of the zoledronic acid is within 90 days of the repair of the hip fracture.
4. A use according to claim 1 or method according to claim 2, wherein administration of the zoledronic acid is within 60 days of the repair of the hip fracture.
5. A use according to claim 1 or method according to claim 2, wherein administration of the zoledronic acid is within 42 days of the repair of the hip fracture.
6. A use according to claim 1 or method according to claim 2, wherein administration of the zoledronic acid is within 1-7 days of the repair of the hip fracture.
7. A use according to claim 1 or method according to claim 2, wherein the medicament is for intravenous administration.
8. A use according to claim 1 or method according to claim 2, wherein the medicament is in unit dose form and the effective amount of zoledronic acid is 5 mg.
9. A use according to claim 1 or method according to claim 2, wherein the zoledronic acid is the free acid.
10. A use or method according to claim 5, wherein the zoledronic acid is the free acid.
11. A use or method according to claim 10, wherein the effective amount of the free acid is 5 mg for administration intravenously over a 15-minute period.

12. A use according to claim 1 or method according to claim 2, wherein the zoledronic acid is administered intermittently such that the period between administrations of the effective amount of zoledronic acid is at least about 6 months.
13. A use or method according to claim 12, wherein the period between administrations is about 1 year.
14. A use according to claim 1 or method according to claim 2, wherein said patient is administered vitamin D2 prior to administration of the zoledronic acid.
15. A use or method according to claim 14, wherein the vitamin D2 is administered at least 14 days prior to administration of the zoledronic acid.
16. A use according to claim 1 or method according to claim 2, wherein the patient is administered a vitamin D supplement on a daily basis.
17. A use according to claim 1 or method according to claim 2, wherein the patient is administered a calcium supplement on a daily basis.